About Soteria Biotherapeutics

Soteria Biotherapeutics is developing switchable bispecific T-cell engagers using its T-LITE™ platform to treat solid tumors in cancer patients. This technology enables pulsatile activation of antibody therapies, resulting in safer treatments with reduced side effects and improved dosing efficacy.

```xml <problem> Existing bispecific T-cell engager therapies for solid tumors can cause significant side effects due to continuous T-cell activation, limiting dosing and efficacy. This toxicity stems from the inability to precisely control the duration and intensity of T-cell engagement, leading to off-target effects and systemic immune activation. </problem> <solution> Soteria Biotherapeutics is developing switchable bispecific T-cell engagers that use its T-LITE™ platform to enable pulsatile activation of antibody therapies. This approach allows for controlled, intermittent engagement of T-cells with tumor cells, reducing off-target toxicity and improving the therapeutic window. By precisely modulating T-cell activity, the T-LITE™ platform aims to deliver safer and more efficacious treatments for patients with solid tumor cancers. The technology enables higher dosing and reduced side effects compared to traditional bispecific T-cell engagers. </solution> <features> - T-LITE™ platform for switchable activation of bispecific antibody therapies - Pulsatile T-cell activation to minimize off-target toxicity - Enhanced dosing capabilities due to improved safety profile - Bispecific engagers designed to target specific solid tumor antigens </features> <target_audience> The primary target audience includes cancer patients with solid tumors who may benefit from safer and more effective bispecific T-cell engager therapies, as well as oncologists and researchers focused on immuno-oncology treatments. </target_audience> ```

What does Soteria Biotherapeutics do?

Where is Soteria Biotherapeutics located?

Soteria Biotherapeutics is based in San Mateo, Philippines.

When was Soteria Biotherapeutics founded?

Soteria Biotherapeutics was founded in 2018.

How much funding has Soteria Biotherapeutics raised?

Soteria Biotherapeutics has raised 42000000.

Location

San Mateo, Philippines

Founded

2018

Funding

42000000

Employees

3 employees

Major Investors

Roche Venture Fund, 5AM Ventures

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Soteria Biotherapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

soteriabiotherapeutics.com 2K+

Crunchbase

Founded 2018 – San Mateo, Philippines

Funding

Estimated Funding

$20M+

Major Investors

Roche Venture Fund, 5AM Ventures

Team (<5)

No team information available.

Company Description

Problem

Existing bispecific T-cell engager therapies for solid tumors can cause significant side effects due to continuous T-cell activation, limiting dosing and efficacy. This toxicity stems from the inability to precisely control the duration and intensity of T-cell engagement, leading to off-target effects and systemic immune activation.

Solution

Soteria Biotherapeutics is developing switchable bispecific T-cell engagers that use its T-LITE™ platform to enable pulsatile activation of antibody therapies. This approach allows for controlled, intermittent engagement of T-cells with tumor cells, reducing off-target toxicity and improving the therapeutic window. By precisely modulating T-cell activity, the T-LITE™ platform aims to deliver safer and more efficacious treatments for patients with solid tumor cancers. The technology enables higher dosing and reduced side effects compared to traditional bispecific T-cell engagers.

Features

T-LITE™ platform for switchable activation of bispecific antibody therapies

Pulsatile T-cell activation to minimize off-target toxicity

Enhanced dosing capabilities due to improved safety profile

Bispecific engagers designed to target specific solid tumor antigens

Target Audience

The primary target audience includes cancer patients with solid tumors who may benefit from safer and more effective bispecific T-cell engager therapies, as well as oncologists and researchers focused on immuno-oncology treatments.